Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations
- 12 June 2024
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 150, 107553
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- FGFR families: biological functions and therapeutic interventions in tumorsMedcomm, 2023
- Infigratinib: First ApprovalDrugs, 2021
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 BindingCell, 2020
- Recent advance in the development of novel, selective and potent FGFR inhibitorsEuropean Journal of Medicinal Chemistry, 2020
- A Comparative Analysis of the Molecular Interaction Techniques for In Silico Drug DesignInternational Journal of Peptide Research and Therapeutics, 2019
- 2-Oxo-3, 4-dihydropyrimido[4, 5- d ]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitorsEuropean Journal of Medicinal Chemistry, 2017
- Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1‐driven leukemia/lymphomasInternational Journal of Cancer, 2017
- The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical StudyEBioMedicine, 2015
- A Structure-Guided Approach to Creating Covalent FGFR InhibitorsChemistry & Biology, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009